Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Furosemide + potassium chloride is a fixed-dose combination of two active pharmaceutical ingredients used primarily in the management of edema (fluid retention) associated with conditions such as congestive heart failure, liver cirrhosis, and renal disease. Furosemide is a loop diuretic that acts by inhibiting sodium and chloride reabsorption in the kidneys' loop of Henle, leading to increased urine output and excretion of water and electrolytes. This diuretic effect can cause significant loss of potassium; therefore, potassium chloride is co-administered to prevent or correct hypokalemia (low blood potassium). Potassium chloride serves as an electrolyte supplement to maintain normal cardiac and neuromuscular function. The combination improves patient compliance compared to separate administration[3][4][9]. Common side effects include gastrointestinal disturbances (nausea, vomiting), dehydration, electrolyte imbalances (including decreased sodium or magnesium), increased uric acid levels, and rarely cardiac arrhythmias if not properly monitored[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on furosemide + potassium chloride.